CABA Stock Overview
A clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Cabaletta Bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.03 |
| 52 Week High | US$26.35 |
| 52 Week Low | US$2.96 |
| Beta | 2.42 |
| 11 Month Change | -38.23% |
| 3 Month Change | -38.04% |
| 1 Year Change | -83.12% |
| 33 Year Change | -72.35% |
| 5 Year Change | -77.05% |
| Change since IPO | -69.70% |
Recent News & Updates
Cabaletta: Biotech With Large Potential, Interesting Bottom Pattern, Plenty Of Cash
Oct 22We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely
Sep 04
Cabaletta Bio: Next Data Readout Needs To Be Mic Drop Moment
Jun 28Recent updates
Cabaletta: Biotech With Large Potential, Interesting Bottom Pattern, Plenty Of Cash
Oct 22We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely
Sep 04Cabaletta Bio: Next Data Readout Needs To Be Mic Drop Moment
Jun 28Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans
May 22Cabaletta Bio: Two Differentiated CAR-T Platforms To Carry It Forward
Jan 31Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans
Dec 28Here's Why We're Not Too Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Situation
Sep 12Here's Why We're Not Too Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Situation
Jun 04Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans
Feb 11We Think Cabaletta Bio (NASDAQ:CABA) Needs To Drive Business Growth Carefully
Oct 20We Think Cabaletta Bio (NASDAQ:CABA) Needs To Drive Business Growth Carefully
Jul 07Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans
Mar 24We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely
Dec 09We're Not Very Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Rate
Aug 05Cabaletta Bio EPS beats by $0.08
May 03Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans
Apr 12What Percentage Of Cabaletta Bio, Inc. (NASDAQ:CABA) Shares Do Insiders Own?
Feb 19
Chardan Capital initiates Cabaletta Bio with Buy rating
Jan 08We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely
Dec 28Dosing underway in Cabaletta Bio's DSG3-CAART study in a rare skin blistering disorder
Dec 09Cabaletta Bio +5% on Q3 results, pipeline update
Nov 10Shareholder Returns
| CABA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -32.1% | -10.3% | -2.1% |
| 1Y | -83.1% | 13.6% | 29.6% |
Return vs Industry: CABA underperformed the US Biotechs industry which returned 13.6% over the past year.
Return vs Market: CABA underperformed the US Market which returned 29.6% over the past year.
Price Volatility
| CABA volatility | |
|---|---|
| CABA Average Weekly Movement | 14.4% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CABA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CABA's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 155 | Steven Nichtberger | www.cabalettabio.com |
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company’s lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis.
Cabaletta Bio, Inc. Fundamentals Summary
| CABA fundamental statistics | |
|---|---|
| Market cap | US$148.10m |
| Earnings (TTM) | -US$104.16m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.4x
P/E RatioIs CABA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CABA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$104.16m |
| Earnings | -US$104.16m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.13 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CABA perform over the long term?
See historical performance and comparison